SEATTLE, Sept. 15, 2017 /PRNewswire-USNewswire/ -- Concure Oncology, parent company of Breast Microseed Treatment®, announces the appointment of Scott Armstrong, former President and CEO of Group Health Cooperative, to its Board of Directors: http://www.breastmicroseed.com/about-us/board-of-directors.aspx
By joining Concure's Board and supporting the advancement of Breast Microseed Treatment, Armstrong continues his advocacy for patient-centric care. He has spent his career advancing evidence-driven, innovative approaches to improving health, and is an evangelist for healthcare that reaches beyond the doctor's office into the community. CEO Sandra Rorem said, "We are very pleased to have Scott join our Board. His background, expertise and leadership in the acceleration of evidence-based medicine align with our company's mission and vision. I am very enthusiastic about this appointment and know that he will be an excellent addition."
"Through decades of experience with how large health systems and the clinicians who practice in them operate, I know how these systems can learn about, master, and adopt new approaches to better health. I've seen this happen with tremendous benefit for thousands of patients, and I'm confident that this treatment is on the verge of becoming an approach to treating breast cancer that changes thousands of women's lives for the better," said Armstrong of Concure's post-lumpectomy radiation therapy that's One Time, One Hour.
Earlier this year, Armstrong wrapped up a distinguished 31-year commitment to Group Health Cooperative, an integrated healthcare provider and not-for-profit health plan that has been nationally recognized for delivering some of the nation's highest quality care. Group Health employed more than 1,000 providers practicing in 25 Group Health-owned and operated medical centers and contracted hospitals in WA state. The company, which employed more than 7,500 staff, had operating revenue of more than $3.8 billion in 2016.
Armstrong, who has a Masters Degree in Health Services Administration from the University of Wisconsin, started with Group Health in 1986 and quickly moved through its leadership ranks. He held positions including VP of Network Services, Executive VP/Chief Administrative Officer, Executive VP/Chief Operating Officer, and then led the company as President and CEO for 12 years. Under his leadership, Group Health led the healthcare industry in the early adoption of electronic medical records, designing an effective patient centered medical home, and proving the value of shared decision-making.
Before leaving the company, he oversaw the acquisition of the nationally recognized health plan by Kaiser Permanente, which closed on February 1, 2017. He worked with his Board and executive leadership team to consider the acquisition, negotiate the agreement, and successfully gain all necessary approvals to close the deal.
Regarding Concure's team, Armstrong stated that, "Having met with and learned about dozens of start-up companies in healthcare services, none have the same depth of professionalism, experience, understanding of how healthcare works, and compassion for the women whose health is the focus of this service. The governing board and leadership team are outstanding, and should give us all great confidence in its success."
Breast Microseed Treatment® - Focused on Life After Cancer
For more information call 844-267-4636, or visit www.breastmicroseed.com.
SOURCE Concure Oncology/Breast Microseed, Inc.